Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review
LA Visser, C Louapre, CA Uyl-de Groot… - Multiple Sclerosis and …, 2020 - Elsevier
Background Considering the multiple treatments approved for multiple sclerosis (MS) by the
Food and Drug Administration (FDA) and European Medicines Agency (EMA), determining a …
Food and Drug Administration (FDA) and European Medicines Agency (EMA), determining a …
[HTML][HTML] Real-world assessment of quality of life in patients with relapsing remitting multiple sclerosis treated with teriflunomide for two years: patient-reported …
E Dardiotis, G Perpati, M Borsos, I Nikolaidis… - Neurology and …, 2022 - Springer
Introduction Multiple sclerosis (MS) is a highly heterogeneous inflammatory disease of the
central nervous system. Patient-reported outcomes (PROs) in a real-world clinical setting …
central nervous system. Patient-reported outcomes (PROs) in a real-world clinical setting …
[PDF][PDF] Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported …
EDGPM Borsos, INDTG Deretzi - 2022 - researchgate.net
Introduction: Multiple sclerosis (MS) is a highly heterogeneous inflammatory disease of the
central nervous system. Patient-reported outcomes (PROs) in a real-world clinical setting …
central nervous system. Patient-reported outcomes (PROs) in a real-world clinical setting …
[PDF][PDF] The potential of a novel cell-based therapy delivery implant in multiple sclerosis: an early health technology assessment
L VIsser - 2021 - repub.eur.nl
Multiple sclerosis (MS) is an immune-mediated, demyelinating disease of the CNS, affecting
2.3 million people worldwide (50, 51). Patients with a clinically isolated syndrome (CIS) or …
2.3 million people worldwide (50, 51). Patients with a clinically isolated syndrome (CIS) or …
Drugs that act on the immune system: Immunosuppressive and immunostimulatory drugs
C Walker, SD Ray - Side Effects of Drugs Annual, 2019 - Elsevier
Abstract Side Effects of Drugs Annual is an annual publication including the most recently
published adverse effects and toxicities associated with medications. The series …
published adverse effects and toxicities associated with medications. The series …